Watch TYRA. Know when insiders buy.
One email the day a filing lands. Free.
TYRA
Tyra Biosciences, Inc.
22.03
−1.51 −6.41%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
48
WATCH · insiders 56, shorts 39
Insiders, 90 days
+$20K
net buying · 1 buy, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.3BP/E —DIV YIELD —FCF YIELD -8.36%REV TTM —NET INCOME −$148.6MNET CASH —52W 12.15 – 39.61SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$49M | −$45.6M | — | -0.69 | −$31.1M | $66K | −$31.1M | Aug 4 |
| Q1 2026 · Mar 31 | — | — | — | −$42M | −$39.3M | — | -0.64 | −$32.6M | $88K | −$32.7M | Aug 4 |
| Q4 2025 · Dec 31derived | — | — | — | −$36.5M | −$33.8M | — | -0.56 | −$23.6M | $57K | −$23.7M | Mar 2 |
| Q3 2025 · Sep 30 | — | — | — | −$32.9M | −$29.9M | — | -0.50 | −$22.4M | $39K | −$22.4M | Nov 5 |
| Q2 2025 · Jun 30 | — | — | — | −$31.5M | −$28.1M | — | -0.47 | −$23.7M | $31K | −$23.7M | Aug 4 |
| Q1 2025 · Mar 31 | — | — | — | −$31.9M | −$28.1M | — | -0.47 | −$25.5M | $14K | −$25.5M | Aug 4 |
| Q4 2024 · Dec 31derived | — | — | — | −$29.7M | −$25.6M | — | -0.43 | −$19.6M | $6K | −$19.6M | Mar 2 |
| Q3 2024 · Sep 30 | — | — | — | −$28.6M | −$24M | — | -0.41 | −$17.9M | $52K | −$17.9M | Nov 5 |
| Q2 2024 · Jun 30 | — | — | — | −$23.5M | −$18.7M | — | -0.32 | −$10.3M | $470K | −$10.7M | Nov 5 |
| Q1 2024 · Mar 31 | — | — | — | −$22.3M | −$18.2M | — | -0.35 | −$22M | $136K | −$22.2M | Nov 5 |
| Q4 2023 · Dec 31derived | — | — | — | −$25.6M | −$22.8M | — | -0.53 | −$13.5M | $603K | −$14.1M | Mar 27 |
| Q3 2023 · Sep 30 | — | — | — | −$24M | −$21.2M | — | -0.49 | −$17.1M | $83K | −$17.2M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$132.8M | −$119.9M | — | -2.01 | −$95.1M | $141K | −$95.3M | — | — |
| FY2024 · to Dec 31 | — | — | −$104.2M | −$86.5M | — | -1.51 | −$69.8M | $664K | −$70.4M | — | — |
| FY2023 · to Dec 31 | — | — | −$79.9M | −$69.1M | — | -1.62 | −$50.1M | $770K | −$50.9M | — | — |
| FY2022 · to Dec 31 | — | — | −$58.9M | −$55.3M | — | -1.32 | −$50.3M | $559K | −$50.8M | — | — |
| FY2021 · to Dec 31 | — | — | −$26.3M | −$26.3M | — | -1.91 | −$23.7M | $661K | −$24.4M | — | — |
| FY2020 · to Dec 31 | — | — | −$9.3M | −$9.3M | — | -6.05 | −$7.8M | $312K | −$8.1M | — | — |
Every number comes from Tyra Biosciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.